4.6 Review

The secretome of endothelial progenitor cells: a potential therapeutic strategy for ischemic stroke

期刊

NEURAL REGENERATION RESEARCH
卷 16, 期 8, 页码 1483-1489

出版社

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1673-5374.303012

关键词

antioxidants; cell-based therapy; cell-free therapy; endothelial progenitor cells; inflammatory cytokines; regenerative medicine; secretome; stroke; vasodegeneration; vasorepair

向作者/读者索取更多资源

Ischemic stroke remains a significant cause of mortality and morbidity worldwide. While thrombolysis with recombinant tissue plasminogen activator is the primary pharmacological therapy, its narrow therapeutic window limits its application to less than 1% of stroke patients globally each year. Endothelial progenitor cells (EPCs) have potential as a therapeutic beyond the acute phase of stroke, but their limited availability and early senescence in culture conditions hinder their efficacy.
Ischemic stroke continues to be a leading cause of mortality and morbidity in the world. Despite recent advances in the field of stroke medicine, thrombolysis with recombinant tissue plasminogen activator remains as the only pharmacological therapy for stroke patients. However, due to short therapeutic window (4.5 hours of stroke onset) and increased risk of hemorrhage beyond this point, each year globally less than 1% of stroke patients receive this therapy which necessitate the discovery of safe and efficacious therapeutics that can be used beyond the acute phase of stroke. Accumulating evidence indicates that endothelial progenitor cells (EPCs), equipped with an inherent capacity to migrate, proliferate and differentiate, may be one such therapeutics. However, the limited availability of EPCs in peripheral blood and early senescence of few isolated cells in culture conditions adversely affect their application as effective therapeutics. Given that much of the EPC-mediated reparative effects on neurovasculature is realized by a wide range of biologically active substances released by these cells, it is possible that EPC-secretome may serve as an important therapeutic after an ischemic stroke. In light of this assumption, this review paper firstly discusses the main constituents of EPC-secretome that may exert the beneficial effects of EPCs on neurovasculature, and then reviews the currently scant literature that focuses on its therapeutic capacity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据